877397-71-2

Basic information

• Product Name: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
• Synonyms: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine;3-[[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]oxy]pyridin-2-amine;2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-
• CAS NO: 877397-71-2
• Molecular Formula: C13H11Cl2FN2O
• Molecular Weight: 301
• Mol File: 877397-71-2.mol
• Article Data: 33

Chemical Properties

• Appearance: /
• Density: 1.400
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(877397-71-2)
• EPA Substance Registry System: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(877397-71-2)

Safety Data

• Hazardous Substances Data: 877397-71-2(Hazardous Substances Data)

Usage

General Description

(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine is a chemical compound with the molecular formula C14H11Cl2F2N3O. It is an amine derivative containing a pyridine ring and a fluorophenyl group. (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine is a potential drug candidate and may have pharmaceutical applications due to its structure and properties. It is important to handle this chemical with care and follow proper safety guidelines when working with it in a laboratory setting.

Upstream product

• 877397-70-1 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethyoxyl)-2-nitropyridine 
• 877397-65-4 (S)‐1‐(2,6-dichloro-3-fluorophenyl)ethanol 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 
• 54231-35-5 3-fuoro-2-nitropyridine 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 877399-98-9 C₉H₉Cl₂FO₃S 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 1229457-91-3 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate 
• 756521-08-1 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine 

Downstream Products

• 1613147-74-2 (R)-tert-butyl 5-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)isoindoline-2-carboxylate 
• 1613147-76-4 (R)-5-(2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-7-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613147-75-3 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1,2,3,4-tetrahydroisoquinoline-7-yl)pyridin-2-amine 
• 1613147-78-6 (R)-5-(2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613147-83-3 (R)-5-(2-(tert-butoxycarbonyl)-8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613147-79-7 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)pyridin-2-amine 
• 1613147-93-5 5-(2-(tert-butoxycarbonyl)-4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613147-99-1 5-(2-(tert-butoxycarbonyl)-4-((tetrahydro-2H-pyran-2-yl)oxy)-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613148-01-8 5-(2-(tert-butoxycarbonyl)-1-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613148-03-0 (R)-N,N-bis(tert-butoxycarbonyl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)pyridin-2-amine 
• 1613148-02-9 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)pyridin-2-amine 
• 1613148-05-2 (R)-N,N-bis(tert-butoxycarbonyl)-5-(6-(tert-butoxycarbonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613148-04-1 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)pyridin-2-amine 
• 1613148-07-4 (R)-N,N-bis(tert-butoxycarbonyl)-5-(6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 

Relevant articles and documents

Preparation method of deuterated crizotinib and derivatives thereof

The invention relates to a preparation method of deuterated crizotinib and derivatives thereof, and belongs to the technical field of synthesis of medical compounds. Four deuterated crizotinib with different configurations are synthesized, the influence of the deuterated position and different chirality of the deuterated crizotinib on the biological activity and the drug metabolism property of thecrizotinib is investigated, and the result shows that the deuterated crizotinib and the crizotinib have similar anti-cancer activity. Compared with a deuterated crizotinib raceme and crizotinib, thedeuterated crizotinib has certain physicochemical property advantages, has good anticancer application prospects, and provides a new compound for synthesis of novel antitumor drugs. The resolution ofthe racemate phenylethanol derivative is a key step for synthesizing the deuterated crizotinib, the ee value of the racemate phenylethanol derivative directly influences the ee value of a final product, and the resolution method has the characteristics of easiness in operation, low cost and the like.

Novel pyridine derivatives having inhibition activity against SHIP2 and pharmaceutical compositions with the components

The present invention relates to a pyridine derivative and/or a use as a SHIP2 inhibitor. The present invention relates to a pyridine derivative of chemical formula I or a pharmaceutically acceptable salt thereof, a method for preparing the compounds, and a pharmaceutical composition containing the compounds as an active ingredient. The pyridine derivative and pharmaceutically acceptable salt thereof is useful as drugs for the treatment of diseases related to SHIP2, such as Alzheimerandprime;s dementia, hypertension, cancer, and diabetes.COPYRIGHT KIPO 2021

Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants

Despite the initial benefit demonstrated in clinical setting with ALK inhibitors, the challenging resistant mutants (F1174L, L1196M and G1202R) invariably developed. In this work, a series of 2-aminopyridine derivatives were designed and synthesized by C-5 position incorporation of a 2-pyridone moiety and bioisosteric replacement of the C-3 position linkers. Optimization of the 2-aminopyridine derivatives led to the identification of hit 18d displaying a significant growth inhibition against a variety of ALK-addicted cancer cells. Especially in the case of ALK-positive Karpas-299 cell, 18d exhibited excellent anti-proliferative potency with an IC50 value of about 40 nM. Moreover, 18d demonstrated encouraging activities against wild-type ALK (19 nM), ROS1 (2.3 nM) as well as challenging crizotinib-resistant ALKL1196M and ALKG1202R mutants with IC50 values of 45 nM and 22 nM, respectively. Additionally flow cytometric analysis indicates that 18d inhibited Karpas-299 cell viability via G1 phase arrest. Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants.